Regeneron Stock Rockets on Strong Q3, Dupixent Boom

Key points: Regeneron (NASDAQ: REGN) shares recently traded around $580–$585 (closing at $585.31 on Oct 27) after a slight pullback earlier in the month ^[1]. Over the past week REGN is up roughly 1–2%, recovering from a low in the high $570s ^[2]. In its Oct. 28 earnings release, Regeneron reported Q3 2025 revenue of $3.75 billion (+1% y/y), led by a 27% jump in Dupixent (its eczema/asthma drug) to $4.86 billion ^[3]. The company also won FDA approval for Libtayo in a high-risk skin cancer indication (first-ever immunotherapy in that setting), and positive EU reviews for Libtayo and Dupixent ^[4]. Wall Street analysts have largely “buy” ratings on REGN: the consensus price target is about $725 (vs. ~$578 current), implying ~25–27% upside ^[5]. The broader biotech sector has been rallying – for example, biotech ETFs (XBI, IBB) are 25–34% higher since spring ^[6], outpacing the 24% gain in the S&P 500 over that span ^[7]. Regeneron is still down from its 2024 highs (above $1,000 in Sept. 2024 ^[8]), but recent drug wins and solid earnings are fueling renewed investor optimism.

Recent Stock Performance

Regeneron shares have been trading in a $576–$585 range over the past week. For example, REGN closed at $575.69 on Oct. 23 and then rebounded to $585.31 by Oct. 27 ^[9]. That roughly 1.7% lift reflects modest confidence among investors after a mid-October dip. Year-to-date REGN is flat to modestly up, but it remains far below its 2024 peak (~$1,050 in Sept. 2024) ^[10]. Compared with large-cap tech and the overall market, biotech stocks have generally seen a stronger run: the Nasdaq Biotechnology Index was +1.6% on Oct. 27 ^[11], and leading biotech ETFs have surged since spring ^[12] while the S&P 500 climbed “only” ~24% in that period ^[13]. This reflects a broad tech recovery and easing regulatory worries in the sector.

Q3 Earnings and Pipeline News

On Oct. 28 Regeneron beat estimates with its Q3 report. Total revenue was $3.75 billion, up about 1% from a year ago ^[14]. The standout was Dupixent (dupilumab): global net sales of Dupixent rose 27% to $4.86 billion (the drug is co-commercialized with Sanofi) ^[15]. Other products were mixed – U.S. sales of the eye drug EYLEA HD grew 10% to $431 million, though total EYLEA (all forms) fell 28% to $1.11 billion ^[16]. Regeneron reported GAAP EPS of $13.62 and non‑GAAP EPS $11.83 ^[17], above analysts’ forecasts (and note the quarter included a one-time R&D charge of $0.68). In short, the quarter confirmed that Dupixent is powering growth while other segments are steady, aligning with expectations.

Management highlighted pipeline successes. In October 2025 the FDA approved Libtayo (cemiplimab) as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma, making it the first and only immunotherapy in that setting ^[18]. (The EU’s drug agency has also issued positive opinions for Libtayo and for Dupixent in new indications ^[19].) Regeneron further announced positive Phase III trial data in areas like myasthenia gravis and rare diseases ^[20], and it expects more FDA decisions on its eye drug EYLEA HD filings late this year. CEO Len Schleifer noted the “commercial strength of Dupixent, EYLEA HD, and Libtayo” and pointed to $663 million in buybacks and a higher dividend in Q3 ^[21] ^[22]. In short, recent weeks have delivered new approvals and data that boost Regeneron’s long-term outlook.

Analyst Views and Forecasts

Most Wall Street analysts remain bullish on REGN. Consensus ratings are mostly Buy/Hold, with only a few Holds or Underperforms. Analysts’ price targets cluster around $700–$750. For instance, one recent survey found Regeneron “trades near $578/share, while the average analyst price target sits around $725/share,” implying roughly 25–26% upside ^[23]. (Another report noted analysts see 15 Buys, 6 Holds, 1 Sell for REGN ^[24].) These targets align with Regeneron’s solid fundamentals: consensus estimates call for about 4% annual revenue growth through 2027 and stable profit margins ^[25] ^[26]. Regeneron’s forward price/earnings ratio is around 15× – modest by biotech standards – reflecting the stock’s decline from last year.

Valuation models suggest further gains over the medium term. In one analysis, a “guided valuation” gave Regeneron a fair price near $734 by 2027, about 27% above today ^[27]. This assumes Dupixent growth continues and new drugs (like the emerging oncology antibodies linvoseltamab and odronextamab) contribute incrementally. Analysts also praise Regeneron’s financial strength: the company has a debt-free balance sheet and strong cash flow, allowing heavy R&D investment and returns to shareholders ^[28] ^[29]. (For example, Regeneron spent nearly $5 billion on R&D and capex in the first 9 months of 2025 ^[30].) Still, analysts warn that growth may stay modest unless new launches exceed expectations, since the eye drug EYLEA faces growing competition in ophthalmology.

A few analysts have trimmed targets. For example, Morgan Stanley recently lowered its Regeneron price target to $756, and Truist cut theirs to $812 (still with buy ratings). But there are no consensus bearish calls: in fact, some firms cite the price weakness earlier in 2025 (shares fell over 40% from 2024 highs) as an opportunity, saying REGN now trades at a relatively low multiple for its earnings growth. In short, analysts see steady but unspectacular gains ahead unless Regeneron can accelerate launches. The average target around $725 ^[31] ^[32] suggests about +25% from current levels if forecasts hold.

Biotech Sector Context and Competitors

Regeneron’s stock moves occur in a strong biotech market. Broad biotech indexes and funds have rallied this year: the SPDR Biotech ETF (XBI) is up about 34% since April, and the iShares Biotech ETF (IBB) is up ~25% ^[33]. Even after lagging the S&P for years, biotech leaders have caught a bid on easing FDA uncertainties. By comparison, the S&P 500’s April-to-now gain is ~24% ^[34]. Regeneron’s peers are in similar boats: top biotech companies (Vertex, Gilead, Amgen, etc.) have also seen gains ^[35] as investors focus on their pipelines and dividends. For example, IBB’s largest holdings include Vertex (VRTX), Gilead (GILD) and Amgen (AMGN) ^[36] – all big firms with mature drug portfolios.

The recent FDA and earnings news may help Regeneron catch up with these peers. Unlike some smaller biotech stocks that face binary FDA risks, Regeneron has a diversified pipeline. Its Dupixent franchise (for asthma, eczema, nasal polyps, etc.) remains a reliable cash cow, while next-generation antibodies (like odronextamab and linvoseltamab) could be future growth drivers in cancer. Meanwhile, obesity/weight-loss drugs (a hot area) have not been a direct factor yet for Regeneron, unlike for Eli Lilly and Novo Nordisk, but Regeneron is exploring its own metabolic therapies.

Overall, the story for REGN stock is that of a quality biotech compounder. It’s not the fastest-growing name, but it has durable products and finances. Recent developments – above-target Q3 results, a breakthrough cancer drug approval (Libtayo), and positive European reviews – are reinforcing the bull case. With a depressed stock price relative to its fundamentals, many analysts believe Regeneron has room to run if it continues executing. Based on current forecasts, the consensus sees upside in the high single-digits to 20% in 2026 and roughly 25–27% total gain by 2027 ^[37] ^[38]. Investors will watch the upcoming earnings call and any guidance updates, but for now Regeneron is riding a positive biotech wave.

Sources: Regeneron’s Oct. 28 press release ^[39] ^[40]; stock price data from Investing.com ^[41]; analyst commentary from TIKR ^[42] ^[43] and Barchart ^[44]; sector data from Nasdaq and GEN News ^[45] ^[46] ^[47].

This Stock has a 5403$ Price Target | This Pharma Stock Will Outperform

Watch this video on YouTube.

References

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

Tuesday Sector Laggards: Utilities and Financials Drag the Market
October 28, 2025, 4:30 PM EDT. Equities are mixed, with Utilities among the day's laggards and Financials not far behind. At midday, Utilities were down about 1.2%, led by Vistra Corp (VST) (-3.6%) and NextEra Energy (NEE) (-2.7%). The XLU ETF fell 1.5% but remains +21.46% YTD, with VST and NEE together making up roughly 16.8% of XLU's holdings. In Financials, the sector dropped 1.1%, as ARE fell 17.9% and BRO -5.2%. The XLF ETF is -0.4% on the day and +11.05% YTD; ARE is -29.09% YTD and BRO -17.99% YTD, with BRO ~0.3% of XLF's holdings. YTD figures frame today's moves in a broader context.
Tuesday Sector Leaders: Materials Lead; Industrials Mixed Midday Trading
October 28, 2025, 4:20 PM EDT. Through midday Tuesday, the Materials sector leads with a 0.3% gain, helped by Sherwin-Williams (SHW) and Nucor (NUE), up about 5.5% and 4.9% intraday. The Materials Select Sector SPDR ETF (XLB) is up 0.4% and 7.66% YTD; SHW and NUE together account for roughly 11.2% of XLB. The Industrial sector is the second best performer, down only 0.1%, with PayPal (PYPL) and United Parcel Service (UPS) rising 8.0% and 7.9% on the day. The Industrial Select Sector SPDR ETF (XLI) is down 0.1% today, but up 19.20% YTD. PYPL is down 11.10% YTD and UPS down 19.73% YTD, with UPS representing about 1.5% of XLI. Across sectors, eight are lower and one up for the S&P 500 components; overall, the mood is mixed.
Fed Rate Cut Expectations Keep Crypto Traders Eyeing Bitcoin and Ethereum
October 28, 2025, 4:10 PM EDT. Markets expect a 25-basis-point Fed rate cut, with a ~97.8% probability, but crypto impacts remain debated. Analysts say ending quantitative tightening could be a tailwind for Bitcoin as inflation tolerance rises, with Bank of America and JPMorgan signaling QT may end soon. Bitcoin traded around $114,850 after a flat day; Ethereum hovered just above $4,100, up versus a week ago but down on the day. Traders believe the cut is largely priced in, and easier policy historically supports crypto and risk assets into 2026. The key question is whether the Fed will unwind QT and how that would affect liquidity and inflation expectations, shaping the near-term moves for BTC, ETH, and broader markets.
Carter's (CRI) Dips After Weak Q3 Results and Restructuring Plan
October 28, 2025, 4:03 PM EDT. Carter's (CRI) shares fell about 3.9% after reporting a weak third-quarter with EPS of $0.32 vs $1.62 a year earlier and revenue of about $758 million. The company announced a sweeping restructuring: closing about 150 stores and cutting 300 corporate jobs, while tariffs and higher product costs pressured margins, leading to suspended fiscal 2025 guidance. The stock is down 41.8% YTD and trades around $31.31, well below a 52-week high of $57.01. The move underscores how trade tensions weigh on consumer discretionary names; a potential easing of tariffs could lift margins and sales. The report notes the sector's sensitivity to international relations and suggests investors may view the decline as meaningful but not a fundamental change in the business.
Great-West Lifeco's Series P Preferred Shares Cross 5.5% Yield Threshold
October 28, 2025, 4:00 PM EDT. Great-West Lifeco Inc's Non-Cumulative First Preferred Shares, Series P (GWO-PRP.TO) traded near $24.53 in Tuesday's session, delivering a yield above 5.5% based on the quarterly dividend (annualized to $1.35). The shares stood at about a 1.60% discount to liquidation preference. Importantly, the non-cumulative feature means missed payments aren't carried forward before resuming a common dividend. On the day, the common shares (GWO.TO) rose modestly alongside a slight uptick in GWO-PRP. Investors should weigh the discount to liquidation and the non-cumulative structure when assessing risk and return in this preferreds issue.

Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside